Ruxolitinib in Treating Patients With Hypereosinophilic Syndrome or Primary Eosinophilic Disorders
Public ClinicalTrials.gov record NCT03801434. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Phase 2 Study of Ruxolitinib in Idiopathic Hypereosinophilic Syndrome and Primary Eosinophilic Disorders
Study identification
- NCT ID
- NCT03801434
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- William Shomali
- Other
- Enrollment
- 10 participants
Conditions and interventions
Conditions
- BCR-JAK2 Fusion Protein Expression
- Blasts 20 Percent or Less of Peripheral Blood White Cells
- Blasts More Than 5 Percent of Bone Marrow Nucleated Cells
- Blasts More Than 5 Percent of Peripheral Blood White Cells
- Blasts Under 20 Percent of Bone Marrow Nucleated Cells
- Chronic Eosinophilic Leukemia, Not Otherwise Specified
- Eosinophilia
- Hepatomegaly
- Hypereosinophilic Syndrome
- JAK2 Gene Mutation
- Splenomegaly
- TEL-JAK2 Fusion Protein Expression
Interventions
- Ruxolitinib Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 14, 2019
- Primary completion
- Dec 29, 2028
- Completion
- Dec 29, 2028
- Last update posted
- Dec 22, 2025
2019 – 2028
United States locations
- U.S. sites
- 4
- U.S. states
- 4
- U.S. cities
- 4
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Stanford Cancer Institute Palo Alto | Palo Alto | California | 94304 | Recruiting |
| OHSU Knight Cancer Institute | Portland | Oregon | 97201 | Terminated |
| University of Utah | Salt Lake City | Utah | 84112 | Terminated |
| Fred Hutchinson cancer research center | Seattle | Washington | 98109 | Terminated |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03801434, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Dec 22, 2025 · Synced Apr 29, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03801434 live on ClinicalTrials.gov.